Short answer
Nautilus Biotechnology Inc (NAUT) filed its Q3 2026 10-Q quarterly report on Oct 27, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $234,000 with net income of −$16M.
Q3 2026 key financials · XBRL
- Revenue
- $234,000
- +23.2% QoQ
- Net income
- −$16M
- −15.2% YoY · −8.1% QoQ
- EPS (diluted)
- −$0.12
- −9.1% YoY · −9.1% QoQ
Source: XBRL data from the Nautilus Biotechnology Inc (NAUT) Q3 2026 10-Q on SEC EDGAR. USD.
Nautilus Biotechnology Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0.2M, versus no material prior-year revenue, driven by $0.2M grant revenue and less than $0.1M service revenue
- Net loss $15.6M vs $13.6M YoY, with R&D expense $10.2M vs $9.6M and SG&A $6.8M vs $5.9M
- Cash, cash equivalents and investments $114.3M at September 30, 2026, funding operations and capital expenditures for at least 12 months
- Operating cash flow use $40.1M vs $38.3M YoY, with $2.4M spent on property and equipment
- Outlook: pre-orders expected early 2027, shipments mid-2027, broadscale assay delayed beyond 2027 general availability and supply disruptions remain a risk
Risk Factors
- Newly added AIML risk, triggered by platform integration, includes alleged bias, inaccurate outputs, intellectual-property infringement, and evolving regulation
- Most material update: broadscale assay unavailable for general availability in 2027, prompting resource reallocation toward proteoform applications
- FDA compliance exposure increased, QMSR effective February 2, 2026, with RUO products potentially subject to clearance or approval requirements
- Commercialization risk: Voyager pre-orders expected early 2027, with instrument shipments beginning mid-2027
- Liquidity risk: available resources expected to fund requirements for at least 12 months, alongside a $125.0 million at-the-market program
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.